JP2015511599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511599A5 JP2015511599A5 JP2014561543A JP2014561543A JP2015511599A5 JP 2015511599 A5 JP2015511599 A5 JP 2015511599A5 JP 2014561543 A JP2014561543 A JP 2014561543A JP 2014561543 A JP2014561543 A JP 2014561543A JP 2015511599 A5 JP2015511599 A5 JP 2015511599A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- polypeptide
- soluble
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 50
- 229920001184 polypeptide Polymers 0.000 claims 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims 26
- 101150096839 Fcmr gene Proteins 0.000 claims 23
- 102000039446 nucleic acids Human genes 0.000 claims 11
- 108020004707 nucleic acids Proteins 0.000 claims 11
- 150000007523 nucleic acids Chemical class 0.000 claims 11
- 239000000178 monomer Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 230000000694 effects Effects 0.000 claims 5
- 108020001507 fusion proteins Proteins 0.000 claims 5
- 102000037865 fusion proteins Human genes 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 3
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 102000051981 human FCMR Human genes 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000003352 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029379 Neutrophilia Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010066130 hyper-IgM syndrome Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612183P | 2012-03-16 | 2012-03-16 | |
| US61/612,183 | 2012-03-16 | ||
| US201261646143P | 2012-05-11 | 2012-05-11 | |
| US61/646,143 | 2012-05-11 | ||
| US201261731428P | 2012-11-29 | 2012-11-29 | |
| US61/731,428 | 2012-11-29 | ||
| PCT/IB2013/001179 WO2013136193A2 (en) | 2012-03-16 | 2013-03-14 | Methods and compositions for modulating toso activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017162409A Division JP6462800B2 (ja) | 2012-03-16 | 2017-08-25 | Ｔｏｓｏ活性を調節するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511599A JP2015511599A (ja) | 2015-04-20 |
| JP2015511599A5 true JP2015511599A5 (enExample) | 2016-04-21 |
| JP6200437B2 JP6200437B2 (ja) | 2017-09-20 |
Family
ID=48747619
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561543A Expired - Fee Related JP6200437B2 (ja) | 2012-03-16 | 2013-03-14 | Ｔｏｓｏ活性を調節するための方法および組成物 |
| JP2017162409A Expired - Fee Related JP6462800B2 (ja) | 2012-03-16 | 2017-08-25 | Ｔｏｓｏ活性を調節するための方法および組成物 |
| JP2018244907A Expired - Fee Related JP6744391B2 (ja) | 2012-03-16 | 2018-12-27 | Ｔｏｓｏ活性を調節するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017162409A Expired - Fee Related JP6462800B2 (ja) | 2012-03-16 | 2017-08-25 | Ｔｏｓｏ活性を調節するための方法および組成物 |
| JP2018244907A Expired - Fee Related JP6744391B2 (ja) | 2012-03-16 | 2018-12-27 | Ｔｏｓｏ活性を調節するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (5) | US9228006B2 (enExample) |
| EP (2) | EP3626254A1 (enExample) |
| JP (3) | JP6200437B2 (enExample) |
| KR (1) | KR102143887B1 (enExample) |
| CN (1) | CN104394880B (enExample) |
| AU (3) | AU2013234046B2 (enExample) |
| CA (1) | CA2867444C (enExample) |
| IL (1) | IL234683B (enExample) |
| WO (1) | WO2013136193A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013234046B2 (en) | 2012-03-16 | 2017-09-07 | University Health Network | Methods and compositions for modulating Toso activity |
| CA2917077A1 (en) | 2013-07-03 | 2015-01-08 | University Health Network | Antibodies to toso |
| RS60387B1 (sr) | 2014-01-15 | 2020-07-31 | Medimmune Llc | Rsv-specifična antitela i njihovi funkcionalni delovi |
| WO2015132672A2 (en) * | 2014-03-07 | 2015-09-11 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| EP3009841A1 (en) * | 2014-10-14 | 2016-04-20 | Bernhard-Nocht-Institut für Tropenmedizin | Detection of IgM Antibodies using an immune complex (IC) ELISA |
| AU2016257000B2 (en) | 2015-05-04 | 2020-05-14 | Apogenix Ag | Single-chain CD40-receptor agonist proteins |
| EP3098237B1 (en) | 2015-05-28 | 2018-08-01 | Universität Zu Köln | Anti-toso chimeric antigen receptor and its use |
| EP3911680A4 (en) | 2019-01-18 | 2022-09-07 | University Health Network | LILRB3 BINDING MOLECULES AND ASSOCIATED USES |
| US12286476B2 (en) * | 2019-02-15 | 2025-04-29 | University Health Network | FCMR-binding molecules and uses thereof |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US6492107B1 (en) | 1986-11-20 | 2002-12-10 | Stuart Kauffman | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
| DE3587814T2 (de) | 1985-03-30 | 1994-11-10 | Marc Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| WO1991004055A1 (en) | 1989-09-15 | 1991-04-04 | Tanox Biosystems, Inc. | Treatment of autoimmune disease |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5686073A (en) | 1990-05-23 | 1997-11-11 | The University Of Iowa Research Foundation | Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| DK0608261T3 (da) | 1991-09-13 | 2003-03-17 | Chiron Corp | Sammensætninger med immunreaktivt hepatitis C virus polypeptid |
| EP0641353A4 (en) | 1991-11-18 | 1997-07-02 | Tanox Biosystems Inc | ANTISENSE OLIGONUCLEOTIDS FOR ISOTYPE-SPECIFIC SUPPRESSION OF IMMUNOGLOBIN PRODUCTION. |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| US5455338A (en) | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
| US6709659B1 (en) | 1996-08-02 | 2004-03-23 | Zymogenetics, Inc. | Antibodies that bind testis-specific insulin homolog polypeptides |
| US6727350B2 (en) | 1997-11-17 | 2004-04-27 | The Board Of Trustees Of The Leland Stanford Junior University | Toso |
| US6555314B1 (en) * | 1998-03-30 | 2003-04-29 | Rigel Pharmaceuticals, Inc. | Toso as a target for drug screening |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| US6683168B1 (en) | 1998-04-21 | 2004-01-27 | Boston Medical Center Corporation | Genes and methods that modulate apoptosis |
| US6322788B1 (en) | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| BR0009772A (pt) | 1999-04-14 | 2002-01-08 | Us Health | Composições contendo imunotoxinas e agentes que inibem a maturação de células dendrìticas para induzir tolerância imune a um enxerto |
| US6939545B2 (en) | 1999-04-28 | 2005-09-06 | Genetics Institute, Llc | Composition and method for treating inflammatory disorders |
| CA2388245C (en) | 1999-10-19 | 2012-01-10 | Kyowa Kirin Co., Ltd. | The use of serum-free adapted rat cells for producing heterologous polypeptides |
| US7074408B2 (en) * | 2000-02-25 | 2006-07-11 | Immunex Corporation | Use of integrin antagonists to inhibit angiogenesis |
| ATE549347T1 (de) | 2000-09-08 | 2012-03-15 | Schering Corp | Gene von säugetiere, und damit verbundene reagentien, methoden |
| CN103333860B (zh) | 2000-10-06 | 2015-07-08 | 协和发酵麒麟株式会社 | 产生抗体组合物的细胞 |
| JPWO2002030954A1 (ja) | 2000-10-06 | 2004-02-19 | 協和醗酵工業株式会社 | 抗体を精製する方法 |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| AU2003298607B9 (en) * | 2002-10-29 | 2011-08-04 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1444989A1 (en) | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| US7610156B2 (en) | 2003-03-31 | 2009-10-27 | Xencor, Inc. | Methods for rational pegylation of proteins |
| KR20070082597A (ko) | 2004-12-30 | 2007-08-21 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 유전자 |
| US7119179B1 (en) | 2005-03-21 | 2006-10-10 | Los Alamos National Security, Llc | Preparation of high nitrogen compound and materials therefrom |
| CN101528914B (zh) | 2006-09-08 | 2014-12-03 | Ambrx公司 | 通过脊椎动物细胞位点特异性并入非天然氨基酸 |
| CN101970472B (zh) * | 2007-06-06 | 2013-10-30 | 研究发展基金会 | Rtef-1变体及其用于抑制血管发生的用途 |
| CA2720651C (en) * | 2008-05-01 | 2020-03-10 | Zymogenetics, Inc. | Levels of blys/april heterotrimers in serum and use in diagnostic methods |
| US20120148581A1 (en) | 2009-08-17 | 2012-06-14 | The Regents Of The University Of California | Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes |
| AU2013234046B2 (en) * | 2012-03-16 | 2017-09-07 | University Health Network | Methods and compositions for modulating Toso activity |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2013
- 2013-03-14 AU AU2013234046A patent/AU2013234046B2/en not_active Ceased
- 2013-03-14 CA CA2867444A patent/CA2867444C/en not_active Expired - Fee Related
- 2013-03-14 CN CN201380023772.0A patent/CN104394880B/zh not_active Expired - Fee Related
- 2013-03-14 JP JP2014561543A patent/JP6200437B2/ja not_active Expired - Fee Related
- 2013-03-14 US US13/831,031 patent/US9228006B2/en not_active Expired - Fee Related
- 2013-03-14 WO PCT/IB2013/001179 patent/WO2013136193A2/en not_active Ceased
- 2013-03-14 EP EP19186831.4A patent/EP3626254A1/en not_active Withdrawn
- 2013-03-14 EP EP13734483.4A patent/EP2825191B1/en active Active
- 2013-03-14 KR KR1020147028977A patent/KR102143887B1/ko not_active Expired - Fee Related
-
2014
- 2014-09-16 IL IL234683A patent/IL234683B/en active IP Right Grant
- 2014-11-12 US US14/539,884 patent/US9624289B2/en not_active Expired - Fee Related
- 2014-11-12 US US14/539,872 patent/US9321824B2/en not_active Expired - Fee Related
- 2014-11-12 US US14/539,879 patent/US9670265B2/en not_active Expired - Fee Related
-
2017
- 2017-05-01 US US15/583,788 patent/US10822388B2/en not_active Expired - Fee Related
- 2017-08-25 JP JP2017162409A patent/JP6462800B2/ja not_active Expired - Fee Related
- 2017-12-05 AU AU2017272172A patent/AU2017272172B2/en not_active Ceased
-
2018
- 2018-12-27 JP JP2018244907A patent/JP6744391B2/ja not_active Expired - Fee Related
-
2019
- 2019-06-28 AU AU2019204594A patent/AU2019204594B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hu et al. | The IL‐17 pathway as a major therapeutic target in autoimmune diseases | |
| Crome et al. | Translational mini-review series on Th17 cells: function and regulation of human T helper 17 cells in health and disease | |
| HRP20190970T1 (hr) | Polipeptidi koji sadrže neglikozilirani fc | |
| JP2018528237A5 (enExample) | ||
| JP2019519215A5 (enExample) | ||
| JP2013541335A5 (enExample) | ||
| JP2016527891A5 (enExample) | ||
| CN107001438A (zh) | 白细胞介素‑15组合物及其用途 | |
| IL278014B2 (en) | Anti-myostatin antibodies, polypeptides containing variable FC regions and methods of use | |
| JP2014523238A5 (enExample) | ||
| JP2017538401A5 (enExample) | ||
| RU2022103870A (ru) | Модифицированный иммунорегуляторный элемент и изменение иммунитета посредством этого элемента | |
| IL269187B2 (en) | Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal | |
| BRPI0806578A8 (pt) | Promotores de lactococcus e usos dos mesmos | |
| JP2015524413A5 (enExample) | ||
| TW201129379A (en) | Anti-Orai1 antigen binding proteins and uses thereof | |
| JP2017524348A5 (enExample) | ||
| NZ739448A (en) | Transgene genetic tags and methods of use | |
| HRP20230145T1 (hr) | Fuzijski polipeptid protiv raka | |
| JP2014034577A5 (enExample) | ||
| AU2017224111A1 (en) | Transposon system and methods of use | |
| JP2011144177A5 (enExample) | ||
| CN107106655A (zh) | 使用白细胞介素‑10治疗疾病和病症的方法 | |
| FI2956471T3 (fi) | Il-1-beetan estäjän koostumus ja sen käyttö | |
| JP2016523910A5 (enExample) |